Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2007

Cobra to Help Pharmexa Take its Bone Disorder Vaccine into Trials

  • Cobra Biomanufacturing will manufacture Pharmexa’s PX107 protein vaccine for use in Phase I trials for bone disorders. The program will include cell banking, process development, and GMP manufacture.

    The vaccine makes use of Pharmexa’s active immunotherapy technology, AutoVac™. The company reports that PX107 induces a polyclonal antibody response toward the protein RANKL, which is increased or imbalanced in the body in diseases such as osteoporosis, rheumatoid arthritis, and bone metastasis with pathological bone destruction.

    Pharmexa will be carrying out the upstream and downstream development of PX107 but requires Cobra’s cGMP manufacturing capabilities to produce the material for Phase I trials, explains David Thatcher, chief executive of Cobra Biomanufacturing.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »